Italy: Dompé signs strategic collaboration with Engitix and joins Series A

copyright Dompe

Milan-based Dompé Farmaceutici, a biopharmaceutical company, has invested in the US$54m Series A funding round of UK-based biopharmaceutical company, Engitix. The companies have also signed a multi-year, multi-programme strategic R&D collaboration to support identification of new treatments against fibrosis and liver-associated solid tumours.  Dompé will provide access to its Exscalate AI drug discovery platform and…

You must be a HMI Subscriber to view this content.

Subscribe Now »